Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer

被引：6

作者：

Morganti, Stefania ^{[1
,2
,3
,4
,5
]}

Tolaney, Sara M. ^{[1
,2
,6
]}

机构：

[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[2] Dana Farber Brigham Canc Ctr, Breast Oncol Program, Boston, MA USA

[3] Harvard Med Sch, Boston, MA USA

[4] Broad Inst & Harvard, Boston, MA USA

[5] Univ Milan, Ist Europeo Oncol, Dept Oncol & Hemato Oncol, Milan, Italy

[6] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2023年 / 37卷 / 01期

关键词：

TNBC; Breast cancer; Immunotherapy; Biomarkers; PDL1; Immune checkpoint inhibitors; PEMBROLIZUMAB PLUS CHEMOTHERAPY; PHASE-III TRIAL; NEOADJUVANT CHEMOTHERAPY; DOUBLE-BLIND; PLACEBO; ATEZOLIZUMAB; PACLITAXEL; MELANOMA; TNBC;

D O I：

10.1016/j.hoc.2022.08.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：133 / 150

页数：18

共 58 条

[1]

Adams S, 2019, ANN ONCOL, V30, P397, DOI [10.1093/annonc/mdy517, 10.1093/annonc/mdy518]

[2] Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study [J].

Alva, Ajjai S. ;

Mangat, Pam K. ;

Garrett-Mayer, Elizabeth ;

Halabi, Susan ;

Hansra, Damien ;

Calfa, Carmen J. ;

Khalil, Maged F. ;

Ahn, Eugene R. ;

Cannon, Timothy L. ;

Crilley, Pamela ;

Fisher, Julie G. ;

Haslem, Derrick S. ;

Shrestha, Sagun ;

Antonelli, Kaitlyn R. ;

Butler, Nicole L. ;

Warren, Sasha L. ;

Rygiel, Andrew L. ;

Ranasinghe, Shamika ;

Bruinooge, Suanna S. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) :2443-+

[3] Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial [J].

Bachelot, Thomas ;

Filleron, Thomas ;

Bieche, Ivan ;

Arnedos, Monica ;

Campone, Mario ;

Dalenc, Florence ;

Coussy, Florence ;

Sablin, Marie-Paule ;

Debled, Marc ;

Lefeuvre-Plesse, Claudia ;

Goncalves, Anthony ;

Reynier, Marie-Ange Mouret ;

Jacot, William ;

You, Benoit ;

Barthelemy, Philippe ;

Verret, Benjamin ;

Isambert, Nicolas ;

Tchiknavorian, Xavier ;

Levy, Christelle ;

Thery, Jean-Christophe ;

L'Haridon, Tifenn ;

Ferrero, Jean-Marc ;

Mege, Alice ;

Del Piano, Francesco ;

Rouleau, Etienne ;

Tran-Dien, Alicia ;

Adam, Julien ;

Lusque, Amelie ;

Jimenez, Marta ;

Jacquet, Alexandra ;

Garberis, Ingrid ;

Andre, Fabrice .

NATURE MEDICINE, 2021, 27 (02) :250-+

[4] Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC) [J].

Barroso-Sousa, Romualdo ;

Li, Tianyu ;

Reddy, Sangeetha ;

Emens, Leisha A. ;

Overmoyer, Beth ;

Lange, Paulina ;

Dilullo, Molly K. ;

Attaya, Victoria ;

Kimmel, Jeffrey ;

Winer, Eric P. ;

Mittendorf, Elizabeth A. ;

Tayob, Nabihah ;

Tolaney, Sara M. .

CANCER RESEARCH, 2022, 82 (04)

[5] Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer [J].

Barroso-Sousa, Romualdo ;

Keenan, Tanya E. ;

Pernas, Sonia ;

Exman, Pedro ;

Jain, Esha ;

Garrido-Castro, Ana C. ;

Hughes, Melissa ;

Bychkovsky, Brittany ;

Umeton, Renato ;

Files, Janet L. ;

Lindeman, Neal I. ;

MacConaill, Laura E. ;

Hodi, F. Stephen ;

Krop, Ian E. ;

Dillon, Deborah ;

Winer, Eric P. ;

Wagle, Nikhil ;

Lin, Nancy U. ;

Mittendorf, Elizabeth A. ;

Van Allen, Eliezer M. ;

Tolaney, Sara M. .

CLINICAL CANCER RESEARCH, 2020, 26 (11) :2565-2572

[6] Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial [J].

Bianchini, G. ;

Huang, C-S. ;

Egle, D. ;

Bermejo, B. ;

Zamagni, C. ;

Thill, M. ;

Anton, A. ;

Zambelli, S. ;

Russo, S. ;

Ciruelos, E. M. ;

Greil, R. ;

Semiglazov, V. ;

Colleoni, M. A. ;

Kelly, C. M. ;

Mariani, G. ;

Del Mastro, L. ;

Smart, C. ;

Valagussa, P. ;

Viale, G. ;

Gianni, L. .

ANNALS OF ONCOLOGY, 2020, 31 :S1145-S1146

[7] Treatment landscape of triple-negative breast cancer - expanded options, evolving needs [J].

Bianchini, Giampaolo ;

De Angelis, Carmine ;

Licata, Luca ;

Gianni, Luca .

NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) :91-113

[8] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 [J].

Burstein, H. J. ;

Curigliano, G. ;

Thurlimann, B. ;

Weber, W. P. ;

Poortmans, P. ;

Regan, M. M. ;

Senn, H. J. ;

Winer, E. P. ;

Gnant, M. .

ANNALS OF ONCOLOGY, 2021, 32 (10) :1216-1235

[9] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[10]

Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9

← 1 2 3 4 5 6 →